[HTML][HTML] Treatment of depression with botulinum toxin

MA Wollmer, M Magid, THC Kruger, E Finzi - Toxins, 2022 - mdpi.com
Injection of botulinum toxin (BoNT) into the glabellar region of the face is a novel therapeutic
approach in the treatment of depression. This treatment method has several advantages …

[HTML][HTML] Botulinum Toxin Treatment for Depression: A New Paradigm for Psychiatry

E Finzi - Toxins, 2023 - mdpi.com
Multiple randomized double-blind placebo-controlled trials have shown that botulinum toxin
A (BoNT/A), when injected into the frown musculature, is an antidepressant. This review …

[HTML][HTML] Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data

H Joulfayan, T Makunts, R Abagyan - Scientific reports, 2023 - nature.com
Rheumatoid arthritis, RA, is a chronic autoimmune disease characterized by joint pain,
tenderness, swelling, and stiffness. This disease affects nearly 1% of the world population …

Long‐term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis

AA Argyriou, EV Dermitzakis… - Acta Neurologica …, 2022 - Wiley Online Library
Abstract Background OnabotulinumtoxinA (BoNTA) demonstrated a positive benefit‐risk in
chronic migraine (CM) patients in PREEMPT I and II phase III trials and many subsequent …

[HTML][HTML] Thyroid hyperplasia and neoplasm adverse events associated with glucagon-like peptide-1 receptor agonists in the Food and Drug Administration Adverse …

T Makunts, H Joulfayan, R Abagyan - JMIRx Med, 2024 - xmed.jmir.org
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are one of the most
commonly used drugs for type 2 diabetes mellitus. Clinical guidelines recommend GLP-1 …

[HTML][HTML] Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system

T Makunts, D Dahill, L Jerome, A de Boer… - Frontiers in …, 2023 - frontiersin.org
3, 4-Methylenedioxymethamphetamine (MDMA) is currently being investigated as an
adjunctive treatment to therapy for posttraumatic stress and other anxiety related disorders in …

Clinical efficacy of escitalopram combined with botulinum toxin A in patients with generalized anxiety disorder and comorbid headache

Y Wang, X Yang, X Ji, M Liu, C Zhou - Psychopharmacology, 2023 - Springer
Background Generalized anxiety disorder (GAD) is a common mental disorder that happens
comorbidly with other diseases. Headache is a common anxiety comorbidity. Previous …

The mind body connection in dermatologic conditions: A literature review

K Mar, JK Rivers - Journal of Cutaneous Medicine and …, 2023 - journals.sagepub.com
Psychodermatology pertains to the relationship between the skin and brain. This review
aims to summarize the evidence of the mind body connection in four psychophysiological …

Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System

T Makunts, H Joulfayan, R Abagyan - medRxiv, 2023 - medrxiv.org
Glucagon receptor-like peptide receptor agonists, GLP-1 RAs, are one of the most
commonly used drugs for type-2 diabetes mellitus. The clinical guidelines recommend GLP …

Toxina Botulínica eo processamento das emoções: uma revisão de literatura sobre os efeitos além da pele

GC de Sousa, TB de Lima… - … Journal of Health …, 2023 - ojs.brazilianjournals.com.br
A toxina botulínica do tipo A é o tratamento estético não cirúrgico mais comum em todo o
mundo. Seu mecanismo de ação consiste em bloquear a liberação da acetilcolina …